Screening mammography beginning at age 40 years: A reappraisal of cost- effectiveness

C. John Rosenquist, Karen K Lindfors

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

BACKGROUND. Several recent studies have added significant information regarding the benefit of screening mammography, especially in the 40-49- years age group. This new information makes it important to reassess the cost-effectiveness of screening. METHODS. A Markov model was used to study the cost-effectiveness of 4 age-related screening strategies: 1) annually from ages 40-79 years; 2) annually from ages 40-64 years and biennially from ages 65-79 years; 3) annually from ages 40-49 years and biennially from ages 50-79 years; and 4) annually from ages 40-79 years in high risk women (10%) and biennially from ages 40-49 years followed by annually from ages 50-79 years in normal risk women (90%). An additional strategy simulating hormone status and estrogen exposure was evaluated. Cost-effectiveness was expressed as marginal cost per year-life saved (MCYLS). RESULTS. The MCYLS varied from $18,800 to $16,100. For all strategies this was within the range of other generally acceptable diagnostic and therapeutic medical procedures. There was a 14% decrease in MCYLS from the least cost-effective to the most cost- effective strategy. CONCLUSIONS. Cost-effectiveness of four age-related mammographic screening strategies was evaluated. The MCYLS for all strategies was within a generally accepted range. With increasing concerns regarding the cost of health care, this information may be useful in health policy decision-making.

Original languageEnglish (US)
Pages (from-to)2235-2240
Number of pages6
JournalCancer
Volume82
Issue number11
DOIs
StatePublished - Jun 1 1998

Fingerprint

Mammography
Cost-Benefit Analysis
Costs and Cost Analysis
Policy Making
Health Policy
Health Care Costs
Decision Making
Estrogens
Age Groups
Hormones

Keywords

  • Breast
  • Carcinoma
  • Cost-effectiveness
  • Mammography
  • Screening

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Screening mammography beginning at age 40 years : A reappraisal of cost- effectiveness. / Rosenquist, C. John; Lindfors, Karen K.

In: Cancer, Vol. 82, No. 11, 01.06.1998, p. 2235-2240.

Research output: Contribution to journalArticle

@article{0b8e3128302a43d6859397f68661b231,
title = "Screening mammography beginning at age 40 years: A reappraisal of cost- effectiveness",
abstract = "BACKGROUND. Several recent studies have added significant information regarding the benefit of screening mammography, especially in the 40-49- years age group. This new information makes it important to reassess the cost-effectiveness of screening. METHODS. A Markov model was used to study the cost-effectiveness of 4 age-related screening strategies: 1) annually from ages 40-79 years; 2) annually from ages 40-64 years and biennially from ages 65-79 years; 3) annually from ages 40-49 years and biennially from ages 50-79 years; and 4) annually from ages 40-79 years in high risk women (10{\%}) and biennially from ages 40-49 years followed by annually from ages 50-79 years in normal risk women (90{\%}). An additional strategy simulating hormone status and estrogen exposure was evaluated. Cost-effectiveness was expressed as marginal cost per year-life saved (MCYLS). RESULTS. The MCYLS varied from $18,800 to $16,100. For all strategies this was within the range of other generally acceptable diagnostic and therapeutic medical procedures. There was a 14{\%} decrease in MCYLS from the least cost-effective to the most cost- effective strategy. CONCLUSIONS. Cost-effectiveness of four age-related mammographic screening strategies was evaluated. The MCYLS for all strategies was within a generally accepted range. With increasing concerns regarding the cost of health care, this information may be useful in health policy decision-making.",
keywords = "Breast, Carcinoma, Cost-effectiveness, Mammography, Screening",
author = "Rosenquist, {C. John} and Lindfors, {Karen K}",
year = "1998",
month = "6",
day = "1",
doi = "10.1002/(SICI)1097-0142(19980601)82:11<2235::AID-CNCR19>3.0.CO;2-V",
language = "English (US)",
volume = "82",
pages = "2235--2240",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Screening mammography beginning at age 40 years

T2 - A reappraisal of cost- effectiveness

AU - Rosenquist, C. John

AU - Lindfors, Karen K

PY - 1998/6/1

Y1 - 1998/6/1

N2 - BACKGROUND. Several recent studies have added significant information regarding the benefit of screening mammography, especially in the 40-49- years age group. This new information makes it important to reassess the cost-effectiveness of screening. METHODS. A Markov model was used to study the cost-effectiveness of 4 age-related screening strategies: 1) annually from ages 40-79 years; 2) annually from ages 40-64 years and biennially from ages 65-79 years; 3) annually from ages 40-49 years and biennially from ages 50-79 years; and 4) annually from ages 40-79 years in high risk women (10%) and biennially from ages 40-49 years followed by annually from ages 50-79 years in normal risk women (90%). An additional strategy simulating hormone status and estrogen exposure was evaluated. Cost-effectiveness was expressed as marginal cost per year-life saved (MCYLS). RESULTS. The MCYLS varied from $18,800 to $16,100. For all strategies this was within the range of other generally acceptable diagnostic and therapeutic medical procedures. There was a 14% decrease in MCYLS from the least cost-effective to the most cost- effective strategy. CONCLUSIONS. Cost-effectiveness of four age-related mammographic screening strategies was evaluated. The MCYLS for all strategies was within a generally accepted range. With increasing concerns regarding the cost of health care, this information may be useful in health policy decision-making.

AB - BACKGROUND. Several recent studies have added significant information regarding the benefit of screening mammography, especially in the 40-49- years age group. This new information makes it important to reassess the cost-effectiveness of screening. METHODS. A Markov model was used to study the cost-effectiveness of 4 age-related screening strategies: 1) annually from ages 40-79 years; 2) annually from ages 40-64 years and biennially from ages 65-79 years; 3) annually from ages 40-49 years and biennially from ages 50-79 years; and 4) annually from ages 40-79 years in high risk women (10%) and biennially from ages 40-49 years followed by annually from ages 50-79 years in normal risk women (90%). An additional strategy simulating hormone status and estrogen exposure was evaluated. Cost-effectiveness was expressed as marginal cost per year-life saved (MCYLS). RESULTS. The MCYLS varied from $18,800 to $16,100. For all strategies this was within the range of other generally acceptable diagnostic and therapeutic medical procedures. There was a 14% decrease in MCYLS from the least cost-effective to the most cost- effective strategy. CONCLUSIONS. Cost-effectiveness of four age-related mammographic screening strategies was evaluated. The MCYLS for all strategies was within a generally accepted range. With increasing concerns regarding the cost of health care, this information may be useful in health policy decision-making.

KW - Breast

KW - Carcinoma

KW - Cost-effectiveness

KW - Mammography

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=0032103495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032103495&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19980601)82:11<2235::AID-CNCR19>3.0.CO;2-V

DO - 10.1002/(SICI)1097-0142(19980601)82:11<2235::AID-CNCR19>3.0.CO;2-V

M3 - Article

C2 - 9610704

AN - SCOPUS:0032103495

VL - 82

SP - 2235

EP - 2240

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -